Phathom Pharmaceuticals
PHAT
6.75
-0.07
-0.95%
Phathom Pharmaceuticals
US · PHAT
#3684 by market cap
Listed 2019
6.75
-0.07
-0.95%
Live - 5344 symbols - heartbeat 491s ago
· 2026-10-08 10:00
Pre-market
7.00
+2.79%
After-hours
6.80
-0.15%
- Market cap
- 545.68M
- P/E (TTM)i
- -5.40
- P/Bi
- -1.59
- EPSi
- -3.03
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on PHAT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -8.46, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +216.93% YoY
Margins
- Gross margin
- 87.09%
- Operating margin
- -91.36%
- Net margin
- -126.35%
Key ratios & quality
- Enterprise valuei
- 625.44M
- Altman Z-Scorei
- -8.46
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0 | 682.00K | 55.25M | 175.11M |
| Gross profit | -- | -- | -- | -- | 0 | 515.00K | 47.28M | 152.51M |
| Selling & admin expenses | 1.21M | 6.94M | 27.52M | 62.74M | 101.00M | 117.93M | 290.66M | 279.72M |
| Research & development | 20.00K | 99.27M | 98.15M | 72.34M | 71.44M | 49.90M | 34.08M | 32.78M |
| Operating profit | -1.23M | -106.22M | -125.67M | -135.08M | -172.44M | -167.31M | -277.47M | -159.99M |
| Pretax profit | -1.29M | -255.13M | -129.07M | -143.88M | -197.72M | -201.59M | -334.33M | -221.25M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -1.29M | -255.13M | -129.07M | -143.88M | -197.72M | -201.59M | -334.33M | -221.25M |
| Basic EPS | 0 | -22 | -4 | -4 | -5 | -4 | -5 | -3 |
| Diluted EPS | -0.15 | -22.45 | -3.88 | -3.89 | -5.05 | -3.93 | -5.29 | -3.03 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 28.52M | 39.50M | -- | 57.58M | 58.30M | 74.27M |
| Gross profit | 24.80M | 34.47M | 43.31M | 49.94M | 46.31M | 59.18M |
| Selling & admin expenses | 94.47M | 85.31M | 51.56M | 48.37M | 54.01M | 55.33M |
| Research & development | 9.18M | 9.08M | 7.03M | 7.49M | 7.77M | 7.81M |
| Operating profit | -78.86M | -59.92M | -15.27M | -5.93M | -15.48M | -3.97M |
| Pretax profit | -94.32M | -75.81M | -29.97M | -21.15M | -30.37M | -17.58M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -94.32M | -75.81M | -29.97M | -21.15M | -30.37M | -17.58M |
| Basic EPS | -1 | -1 | 0 | 0 | 0 | 0 |
| Diluted EPS | -1.31 | -1.05 | -0.41 | -0.29 | -0.37 | -0.21 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 902.00K | 255.60M | 291.37M | 186.53M | 160.51M | 397.43M | 360.13M | 228.97M |
| Cash & ST investments | 879.00K | 243.77M | 287.50M | 183.26M | 155.39M | 381.39M | 297.26M | 129.97M |
| Inventory | -- | -- | -- | -- | 0 | 1.21M | 3.21M | 5.52M |
| Total assets | 902.00K | 257.18M | 295.11M | 189.43M | 164.81M | 413.84M | 378.32M | 259.15M |
| Total current liabilities | 2.19M | 3.75M | 55.52M | 18.92M | 26.24M | 38.78M | 85.73M | 132.04M |
| Short-term debt | 1.95M | 161.00K | 7.83M | 487.00K | 708.00K | 726.00K | 501.00K | 648.00K |
| Long-term debt | -- | 22.78M | 39.63M | 89.67M | 95.26M | 137.84M | 201.41M | 209.09M |
| Total liabilities | 2,188,000.00 | 29,223,000.00 | 100,840,000.00 | 117,275,000.00 | 239,624,000.00 | 486,601,000.00 | 631,898,000.00 | 697,318,000.00 |
| Total equity | -1.29M | 227.96M | 194.27M | 72.16M | -74.81M | -72.76M | -253.58M | -438.17M |
| Retained earnings | -1.29M | -256.42M | -385.49M | -529.37M | -727.09M | -928.69M | -1.26B | -1.48B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 264.90M | 218.88M | 207.78M | 228.97M | 276.57M | 295.92M |
| Cash & ST investments | 212.32M | 149.57M | 135.16M | 129.97M | 180.90M | 182.48M |
| Inventory | 3.17M | 3.43M | 3.61M | 5.52M | 6.51M | 7.71M |
| Total assets | 294.21M | 250.22M | 240.29M | 259.15M | 305.12M | 327.08M |
| Total current liabilities | 74.03M | 91.82M | 93.12M | 132.04M | 125.04M | 153.78M |
| Short-term debt | 316.00K | 238.00K | 591.00K | 648.00K | 667.00K | 670.00K |
| Long-term debt | 203.25M | 205.14M | 207.09M | 209.09M | 163.68M | 164.59M |
| Total liabilities | 632,584,000.00 | 656,054,000.00 | 662,823,000.00 | 697,318,000.00 | 642,075,000.00 | 671,348,000.00 |
| Total equity | -338.38M | -405.83M | -422.53M | -438.17M | -336.96M | -344.27M |
| Retained earnings | -1.36B | -1.43B | -1.46B | -1.48B | -1.51B | -1.53B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -1.02M | -36.51M | -69.69M | -148.46M | -146.53M | -137.58M | -266.77M | -166.78M |
| Depreciation & amortization | 0 | 8.00K | 323.00K | 521.00K | 620.00K | 575.00K | 795.00K | 633.00K |
| Free cash flow | -1.02M | -61.76M | -70.73M | -148.79M | -147.57M | -139.21M | -266.91M | -167.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 2.00K | 191.47M | 88.83M | 0 | 24.60M | 155.46M | 121.78M | 0 |
| Ending cash balance | 879.00K | 243.77M | 287.50M | 183.42M | 155.89M | 384.26M | 300.13M | 132.83M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -84.93M | -62.73M | -14.12M | -5.00M | -15.65M | -1.93M |
| Depreciation & amortization | 177.00K | 172.00K | 156.00K | 128.00K | 110.00K | 114.00K |
| Free cash flow | -84.95M | -62.83M | -14.14M | -5.09M | -15.71M | -1.97M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 0 | 121.97M | 0 |
| Ending cash balance | 215.18M | 152.43M | 138.02M | 132.83M | 183.77M | 185.34M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -225.11 | -61.14 | -108.01 | -- | -- | -- | -- |
| ROA %i | -135.81 | -197.71 | -46.74 | -59.39 | -111.63 | -69.68 | -84.41 | -69.41 |
| ROIC %i | -- | -182.90 | -50.76 | -67.42 | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -23,405.28 | -474.76 | -87.45 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.41 | 68.20 | 5.25 | 9.86 | 6.12 | 10.25 | 4.20 | 1.73 |
| Quick ratioi | 0.41 | 65.04 | 5.18 | 9.69 | 5.92 | 9.88 | 3.92 | 1.58 |
| Debt / assetsi | 216.19 | 9.17 | 16.61 | 48.22 | 58.90 | 33.59 | 53.37 | 81.73 |
| LT debt / equityi | -- | 10.27 | 21.20 | 125.91 | -- | -- | -- | -- |
| Interest coveragei | -98.08 | -60.08 | -27.17 | -20.20 | -6.24 | -3.80 | -3.64 | -2.25 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | -106.28 | -115.93 | -87.53 | -69.41 | -52.49 | -34.32 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -333.35 | -225.79 | -138.77 | -87.45 | -44.64 | -14.87 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.58 | 2.38 | 2.23 | 1.73 | 2.21 | 1.92 |
| Quick ratioi | 3.36 | 2.19 | 2.05 | 1.58 | 2.09 | 1.82 |
| Debt / assetsi | 69.19 | 82.31 | 87.31 | 81.73 | 54.50 | 51.09 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -3.74 | -3.54 | -2.91 | -2.25 | -1.39 | -0.56 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Product revenue, net100.00%
Quote time 2026-10-08 10:00:25 · For reference only, not investment advice and not tailored to your situation.